Simpson Nicholas S, Kummer Timothy M, Drone Holly M, Perlmutter Michael C, Schin Alexander M, Cole Jon B, Driver Brian E, Puskarich Michael A, Martin Maureen E, Bunting Alec J, Robinson Aaron E
Department of Emergency Medicine, Hennepin Healthcare, Minneapolis, Minnesota.
Hennepin EMS, Hennepin Healthcare, Minneapolis, Minnesota.
Prehosp Emerg Care. 2025;29(4):427-434. doi: 10.1080/10903127.2024.2422897. Epub 2024 Nov 19.
The epidemic of opioid use disorder (OUD) remains pervasive in the United States. In an effort to increase the availability and timeliness of medications for opioid use disorder (MOUD), several agencies in the United States (US) offer buprenorphine by prehospital providers to selected patients, though published data remains limited. We describe the preliminary safety and feasibility of training all paramedics within a single agency to administer buprenorphine in the field without online medical control to simultaneously treat opioid withdrawal and initiate MOUD.
Using data from an ongoing quality assurance (QA) database, cases were retrospectively reviewed. Inclusion criteria included administration of buprenorphine by paramedics; cases were excluded if administered prior to EMS arrival on scene (i.e., the patient was given buprenorphine by a bystander or took their own). Data were entered into a REDCap database as part of the ongoing QA process. The primary reported outcome was administration of buprenorphine without complications. Complications were defined as any adverse effects from the administration of medication, including but not limited to new or worsening opioid withdrawal symptoms.
In total, 121 patients met inclusion criteria, 82 were treated for naloxone-induced withdrawal and 39 for withdrawal due to opioid cessation. There were no cases of precipitated withdrawal or worsening of patient condition observed. Adverse effects were limited to three cases of nausea and vomiting post-administration, all of which were present prior to buprenorphine administration. No patients met the primary outcome of adverse effects from medication administration.
In a single prehospital system, the use of buprenorphine appears to be a feasible and safe strategy for treating patients experiencing acute opioid withdrawal.
阿片类药物使用障碍(OUD)在美国仍然普遍存在。为了提高阿片类药物使用障碍药物(MOUD)的可及性和及时性,美国的几个机构让院前急救人员为选定的患者提供丁丙诺啡,不过公开数据仍然有限。我们描述了在单一机构内培训所有护理人员在现场无需在线医疗指导即可使用丁丙诺啡,以同时治疗阿片类药物戒断反应并启动MOUD的初步安全性和可行性。
使用来自一个正在进行的质量保证(QA)数据库的数据进行回顾性病例审查。纳入标准包括护理人员使用丁丙诺啡;如果在急救医疗服务(EMS)到达现场之前使用(即患者由旁观者给予丁丙诺啡或自行服用),则排除这些病例。作为正在进行的QA过程的一部分,数据被录入到一个REDCap数据库中。主要报告的结果是使用丁丙诺啡无并发症。并发症定义为用药后的任何不良反应,包括但不限于新出现的或加重的阿片类药物戒断症状。
共有121名患者符合纳入标准,其中82名接受了纳洛酮诱发的戒断反应治疗,39名接受了因阿片类药物停用引起的戒断反应治疗。未观察到戒断反应加剧或患者病情恶化的情况。不良反应仅限于用药后出现的3例恶心和呕吐,所有这些症状在使用丁丙诺啡之前就已存在。没有患者出现用药不良反应的主要结果。
在单一的院前急救系统中,使用丁丙诺啡似乎是治疗急性阿片类药物戒断患者的一种可行且安全的策略。